Home  - Basic_G - Graft Vs Host Disease

Books Baby Camera Phones Computers Games DVD Electronics Kitchen Magazines Music Garden Software Tools Toys Video Apparel & Accessories Jewelry & Watches Musical Instruments Health & Personal Care Beauty Sports & Outdoors Office Products

e99.com Bookstore

Images

Newsgroups

21-40 of 104    Back | 1  | 2  | 3  | 4  | 5  | 6  | Next 20

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Graft Vs Host Disease:     more books (19)

Cutaneous manifestations of systemic disease: sarcoidosis, GVHD, behcet's disease, and pyoderma gangrenosum.(Dermatology Nursing Essentials: Core Knowledge)(Author ... An article from: Dermatology Nursing by Sue Ann McCann, 2007-02-01 Tacrolimus: An entry from Thomson Gale's <i>Gale Encyclopedia of Cancer, 2nd ed.</i> by Diane Calabrese, 2006 Bacterial endotoxin and graft-versus-host-disease by Richard Hugh Moore, 1988 Specifically induced resistance to graft-versus-host disease in F1 rats;: A dissertation in immunology by Donald Bellgrau, 1978 Diseases caused by reactions of T lymphocytes to incompatible structures of major histocompatibility complex: Academic proefschrift / c Antonius Gerhardus Rolink by Anton G Rolink, 1983

lists with details

21. Entrez PubMed
    Chronic Disease; graft vs host disease*/diagnosis; graft vs host disease*/epidemiology; graft vs host disease*/etiology; graft vs host disease*/therapy  
    http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1

22. Entrez PubMed
    Understanding the cellular mechanisms that lead to graftversus-host disease (GVHD) graft vs host disease/pathology; graft vs host disease/prevention  
    http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1

23. Graft-vs-Host Disease
    graftvs-host disease (GvHD) is a complication that is observed after allogeneic stem cell / bone marrow transplant ..  
    http://www.stjude.org/stem-cell-trans/0,2527,419_4124_6031,00.html
    
    Extractions: @import url(/StJude/CDA/Common/CSS/default.css); @import url(/StJude/CDA/Common/CSS/default_lists.css); @import url(/StJude/CDA/Common/CSS/default_content_types.css); @import url(/StJude/Common/CSS/St_Jude_Clinical_Science); The following browsers support numerous web standards including CSS, XHTML, and the DOM (a universal means of controlling the behavior of web pages): St. Jude Children's Research Hospital Home Clinical Science Home Stem Cell Transplantation Complications/Side Effects Related Topics Symptoms of acute GvHD include rash, yellow skin and eyes due to elevated concentrations of bilirubin, and diarrhea. Acute GvHD is graded on a scale of 1 to 4; grade 4 is the most severe. In some severe instances, GvHD can be fatal. GvHD is more easily prevented than treated. Preventive measures typically include the administration of cyclosporin with or without methotrexate or steroids after stem cell / bone marrow transplant. Alternatively, T lymphocytes are removed from the stem cell graft before it is transplanted.

24. Graft-vs.-host Disease
    CHC Wausau Hospital s Medical Library and Patient Education Center provides research services and healthcare information to physicians,  
    http://www.chclibrary.org/micromed/00049690.html
    
    Extractions: The main problem with transplanting organs and tissues is that the recipient host does not recognize the new tissue as its own. Instead, it attacks it as foreign in the same way it attacks germs, to destroy it. If immunogenic cells from the donor are transplanted along with the organ or tissue, they will attack the host, causing graft vs. host disease. The only transplanted tissues that house enough immune cells to cause graft vs. host disease are the blood and the bone marrow. Blood transfusions are used every day in hospitals for many reasons. Bone marrow transplants are used to replace blood forming cells and immune cells. This is necessary for patients whose cancer treatment has destroyed their own bone marrow. Because bone marrow cells are among the most sensitive to radiation and chemotherapy , it often must be destroyed along with the cancer. This is true primarily of leukemias, but some other cancers have also been treated this way. Even if the donor and recipient are well matched, graft-vs.-host disease can still occur. There are many different elements involved in generating immune reactions, and each person is different, unless they are identical twins. Testing can often find donors who match all the major elements, but there are many minor ones that will always be different. How good a match is found also depends upon the urgency of the need and some good luck.

25. Graft-vs.-host Disease
    a CHORUS notecard document about graftvs.-host disease.  
    http://chorus.rad.mcw.edu/doc/00177.html

26. Graft-vs.-host Disease
    graftvs.-host disease. GvH seen in recipients of bone marrow allografts. small bowel other GI sites. thickened wall; mucosal folds thickened or  
    http://chorus.rad.mcw.edu/to-go/00177.html

27. Graft-vs.-host Disease
    graftvs.-host disease is an immune attack on the recipient by cells from a Both forms of graft-vs.-host disease bring with them an increased risk of  
    http://www.healthatoz.com/healthatoz/Atoz/ency/graft-vs-host_disease.jsp

28. Graft-versus-host Disease - Wikipedia, The Free Encyclopedia
    graftversus-host disease can occur even when HLA-identical sibling are the donors. graft-vs.-host-disease by Ferrara et al. (2nd ed.  
    http://en.wikipedia.org/wiki/Graft-versus-host_disease
    
    Extractions: Graft-versus-host disease is a common complication of allogeneic bone marrow transplantation . After bone marrow transplantation, T cells present in the graft , either as contaminants or intentionally introduced into the host, attack the tissues of the transplant recipient. Graft-versus-host disease can occur even when HLA -identical sibling are the donors. HLA-identical siblings or HLA-identical unrelated donors (called a minor mismatch as opposed to differences in the HLA antigens , which constitute a major mismatch) often still have genetically different proteins that can be presented on the MHC While donor T-cells are undesirable as effector cells of graft-versus-host-disease, they are valuable for engraftment by preventing the recipient's residual immune system from rejecting the bone marrow graft (host-versus-graft). Additionally, as bone marrow transplantation is frequently used to cure malignant disorders (most prominently the leukemias ), donor T-cells have proven to have a valuable graft-versus- tumor effect. A great deal of current research on allogeneic bone marrow transplantation involves attempts to separate the undesirable graft-vs-host-disease aspects of T-cell physiology from the desirable graft-versus-tumor effect.

29. Accessing Article
    Bone Marrow Transplantation is a high quality, peerreviewed journal covering all aspects of clinical and basic haemopoietic stem cell transplantation.  
    http://www.nature.com/uidfinder/10.1038/sj.bmt.1705043
    
    Extractions: Most users gain access to full text articles through a site license. This is available to institutional customers only. For further information visit the Librarian Gateway. Full-text articles are also available through a number of other options: I want to purchase this article Select this option to view this article immediately and access it for seven days. I am already a personal subscriber to Bone Marrow Transplantation Personal subscribers to Bone Marrow Transplantation can view this article. To do this you need to associate your subscription with your registration via the My Account page. If you already have an active online subscription, log in via the login box in the top right-hand corner of this page.

30. National Cancer Institute - Oral Complications Of Chemotherapy And Radiation
    Woo SB, Lee SJ, Schubert MM graftvs.-host disease. Oral involvement in chronic graft-vs-host disease following allogenic bone marrow transplantation.  
    http://www.nci.nih.gov/cancertopics/pdq/supportivecare/oralcomplications/HealthP
    
    Extractions: Graft-versus-Host Disease Patients who have received allogeneic or matched unrelated transplants are at risk for graft-versus-host disease (GVHD).[ ] A related condition referred to as pseudo-GVHD is occasionally reported in autologous hematopoietic stem cell transplant recipients. The lesion can affect oral tissues and often mimics naturally occurring autoimmune diseases such as erosive lichen planus, lupus erythematosus, scleroderma and Sj¶gren’s syndrome. Oral GVHD has also been linked with oral precancerous and malignant lesions.[ Acute GVHD can occur as early as 2 to 3 weeks posttransplant; mucosal erythema and erosion/ulceration are typical manifestations. Chronic oral GVHD changes can be recognized as early as day 70 posttransplant.[

31. Pediatric Graft Vs. Host Disease (GVHD), Pediatric Bone Marrow Transplant, Seatt
    graft vs. host disease is a common side effect of transplants. GVHD occurs when the transplanted or donor cells recognize the patient’s tissues as foreign  
    http://www.seattlecca.org/patientsandfamilies/pediatricCare/pediatricBoneMarrowT
    
    Extractions: Home Pediatric Care Pediatric Bone Marrow Transplant Long Term Follow-up > Graft vs. Host Disease (GVHD) Choose a Diagnosis Autoimmune Diseases Bladder Cancer Blood Disorders Bone Marrow Transplant Breast Cancer Breast Cancer in Men Breast Health Cervical Cancer Colorectal Cancer Endometrial Cancer Gastrointestinal Cancer Prevention Gestational Trophoblastic Disease Gynecologic Cancers Kidney Cancer Leukemia Liver Cancer Lung Cancer Lymphoma Melanoma Mesothelioma Multiple Myeloma Myelodysplastic Synd. Ovarian Cancer Pancreatic Cancer Pediatric Cancer Pediatric Bone Marrow Transplant Prostate Cancer Sarcoma Skin Cancer Stomach Cancer Vulvar Cancer Graft vs. Host Disease (GVHD)

32. Graft-versus-Host Disease, 2nd Edition ISBN 1-57059-534-8
    This book provides a historical perspective of graftvs-host disease as well as the discussion of the mechanisms involved in graft-vs-host disease.  
    http://www.landesbioscience.com/iu/output.php?id=115

33. LTFU - FAQ's - Graft-vs.-Host-Disease
    What is the risk for developing chronic graftvs.-host disease (GVHD) after transplant? What would indicate a need for systemic treatment of chronic GVHD?  
    http://www.fhcrc.org/science/clinical/ltfu/faqs/gvhd.html
    
    Extractions: @import "/wrapper/global.css"; @import "/wrapper/wrapper.css"; Q. What is the risk for developing chronic graft-vs.-host disease (GVHD) after transplant? About 60 percent of patients who receive an allogeneic transplant and are alive at day 100 will develop chronic GVHD. Q. What would indicate a need for systemic treatment of chronic GVHD? Systemic immunosuppressive treatment with a medication like prednisone is not usually necessary for patients who have mild chronic GVHD. For example, someone with a platelet count greater than 100,000 and mild symptoms in just one site, such as the mouth, would probably not require systemic treatment. Someone with chronic GVHD involving multiple sites such as liver and skin or eyes and genital tract, or someone with chronic GVHD and a platelet count less than 100,000 would require systemic therapy. If symptoms are severe, systemic immunosuppressive treatment may be needed even when only a single site is involved. Your doctor, can determine if you need systemic treatment. The LTFU is available to help your doctor in making this decision.

34. Center News - 1/8/04 - Genetic Test Creates Prediction
    HLA mismatches can result in graftvs.-host disease, a condition that causes symptoms ranging from rashes to debilitating or even lethal damage to the  
    http://www.fhcrc.org/pubs/center_news/2004/jan8/sart2.html
    
    Extractions: January 8, 2004 The outcome is in the genes Drs. John Hansen and Ming-Tseh Lin have developed a genetic test for predicting transplant outcome that may help doctors choose the best treatment plan for patients. By BARBARA BERG A simple genetic test could help doctors predict the likelihood that a patient will develop a potentially life-threatening complication after a bone-marrow or stem-cell transplant. New research conducted by Drs. Ming-Tseh Lin, John Hansen and colleagues in the Clinical Research Division and Taiwan reveals that transplant recipients with a common variant of an immune-system regulator gene are half as likely as other patients to develop clinically severe graft-vs.-host disease. The complication occurs when transplanted cells mount a destructive immune reaction against a patient's body. The findings, published in the Dec. 4 issue of the New England Journal of Medicine, suggest that inclusion of the genetic test in a patient's standard pre-transplant evaluation could ultimately help doctors determine the optimum timing and course of treatment.

35. Graft-vs-Host Disease Topic - Unified Search Environment
    graftvs-host disease MSH/EN/D006086 MTH/PN/NOCODE MSH/PM/D006086 MSH/MH/D006086 graft-Versus-host disease MSH/EP/D006086 PDQ/SY/208/04738  
    http://www.use.hcn.com.au/portals/shared/subject.`Graft-vs-Host Disease`/home.ht
    
    Extractions: autoimmune foreign transplant disease Diseases (MeSH Category) Animal Diseases Bacterial Infections and Mycoses Cardiovascular Diseases ... Hemic and Lymphatic Diseases Immunologic Diseases Autoimmune Diseases Blood Group Incompatibility Glomerulonephritis, Membranoproliferative Graft-vs-Host Disease ... Skin and Connective Tissue Diseases

36. Clinical Trial: Thymoglobulin To Prevent Acute Graft Vs. Host Disease (GvHD) In
    Acute lymphocytic leukemia (ALL) graft vs. host disease (GvHD), Drug Thymoglobulin AntiThymocyte Globulin (Rabbit)  
    http://www.clinicaltrials.gov/ct/gui/show/NCT00088543
    
    Extractions: Verified by Genzyme September 2005 Sponsored by: Genzyme Information provided by: Genzyme ClinicalTrials.gov Identifier: Purpose This study involves the use of a drug called Thymoglobulin, which is approved in the USA to treat kidney transplant rejection and in Canada to treat and to prevent kidney transplant rejection. Thymoglobulin is not approved for the treatment or prophylaxis of graft versus host disease in bone marrow transplantation. This study is to evaluate two (2) doses of Thymoglobulin and its safety and effectiveness when used with a "myeloablative" conditioning regimen prior to receiving a stem cell transplant (also called bone marrow transplantation) from a matched, related donor. A myeloablative regimen is typically composed of chemotherapy and radiation and destroys the subject's existing bone marrow. Subjects meeting all inclusion and exclusion criteria and who have a relative with matching (genetically similar) stem cells who are also willing to donate them (i.e. matched-related-donor) are eligible to participate in this study. Following myeloablative therapy, the donor's cells are then transplanted (i.e. infused) into the subject's blood stream.

37. Increased Risk Of Extensive Chronic Graft-versus-host Disease After Allogeneic P
    Cumulative incidence of overall chronic graftversus-host disease (GVHD) was similar in the 2 groups (78% vs 71%), while extensive chronic GVHD was  
    http://www.bloodjournal.org/cgi/content/abstract/105/2/548
    
    Extractions: most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal ... Rights and Permissions PubMed PubMed Citation Articles by Remberger, M. Related Collections Transplantation Brief report Mats Remberger Dietrich W. Beelen Axel Fauser Nadezda Basara Oliver Basu , and From the Centre for Allogeneic Stem Cell Transplantation and Department of Clinical Immunology, Karolinska University Hospital, Stockholm, Sweden; the Department of Bone Marrow Transplantation, University Hospital Essen, Germany; the Clinic of BMT, Haematology and Oncology, Idar-Oberstein, Germany; and the Department of Paediatric Haematology, Oncology and Endocrinology, University Hospital Essen, Germany.

38. September 1992 - Transfusion Associated Graft Vs. Host Disease And Irradiated Bl
    graft vs. host disease is a rare complication of transfusion. TAGVHD has the same features as graft vs. host disease occurring in other settings such as  
    http://www.itxm.org/Archive/tmu9-92.htm
    
    Extractions: TRANSFUSION ASSOCIATED GRAFT VS. HOST DISEASE AND IRRADIATED BLOOD COMPONENTS Darrell J. Triulzi, M.D., Assistant Medical Director, Patient Transfusion Services INTRODUCTION Graft vs. host disease is a rare complication of transfusion. The disease results from transfusion of immunocompetent T cells capable of engrafting and initiating an immune response against recipient antigens. The most susceptible patient groups are those who are severely immunocompromised or are the recipients of directed donations from first-degree relatives. Transfusion associated graft vs. host disease (TAGVHD) can be prevented by gamma irradiation of cellular blood components (red cells, platelets, granulocytes). CLINICAL PRESENTATION TAGVHD has the same features as graft vs. host disease occurring in other settings such as allogeneic bone marrow transplantation. It typically occurs 3-30 days after transfusion of non-irradiated cellular products. The initial manifestations are often a high fever and an erythematous skin rash. Bone marrow aplasia and pancytopenia are also characteristic findings in TAGVHD. Other organs which may be involved include the gastrointestinal tract and liver. The diagnosis is made on the basis of a constellation of clinical features and can be confirmed by biopsy of the skin or other involved organs. This form of GVH has an extremely poor prognosis; the mortality rate approaches 90%. Unfortunately, there are no current effective therapies.

39. Arch Dermatol -- Abstract: Induction Of Hyperacute Graft-vs-Host Disease After D
    Late Appearance of Acute graftvs-host disease After Suspending or Tapering Immunosuppressive Drugs Valks et al. Arch Dermatol 2001;13761-65.  
    http://archderm.ama-assn.org/cgi/content/abstract/135/3/304
    
    Extractions: Vol. 135 No. 3, March 1999 Featured Link E-mail Alerts Observation Article Options Full text PDF Send to a Friend Readers Reply Submit a reply Similar articles in this journal Literature Track Add to File Drawer Download to Citation Manager PubMed citation Articles in PubMed by Fernandez-Herrera J Garcia-Diez A Articles that cite this article ISI Web of Science (4) ... Contact me when this article is cited Topic Collections Hematology/ Hematologic Malignancies Leukemias/ Lymphomas Immunologic Disorders Bone Marrow Transplantation ... Topic Collection Alerts

40. Arch Dermatol -- Abstract: Acute Graft-vs-host Disease In An Immunodeficient New
    Acute graftvs-host disease occurring during the early weeks of life has been We report a case of acute graft-vs-host disease in a female infant with an  
    http://archderm.ama-assn.org/cgi/content/abstract/125/12/1685
    
    Extractions: Vol. 125 No. 12, December 1989 Featured Link E-mail Alerts ARTICLE Article Options Send to a Friend Readers Reply Submit a reply Similar articles in this journal Literature Track Add to File Drawer Download to Citation Manager PubMed citation Articles in PubMed by Tawfik N Jimbow K Contact me when this article is cited N. Tawfik and K. Jimbow Division of Dermatology and Cutaneous Sciences Faculty of Medicine, University of Alberta, Edmonton, Canada. Acute graft-vs-host disease occurring during the early weeks of life has been previously reported as a rare disease entity. We report a case of acute graft-vs-host disease in a female infant with an immunodeficiency that was thought to be secondary to intrauterine or neonatal cytomegalovirus infection or, less likely, to a severe combined

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

21-40 of 104    Back | 1  | 2  | 3  | 4  | 5  | 6  | Next 20